Piper Jaffray Upgrades Cytokinetics (CYTK) to Overweight; Sees 100% Upside
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Cytokinetics (CYTK) Surpasses FY14 Estimates Following Recent Astellas Deal; Roth Cap. Affirms at 'Buy'
February 13, 2015 8:29 AM ESTRoth Capital comments on Cytokinetics (Nasdaq: CYTK) following Q4, FY14 results reported late Thursday. The firm retains a Buy rating and $18 price target on Cytokinetics following the numbers and update.
Analyst Joseph Pantginis noted that Cytokinetics reported FY14 loss of $0.41 per share with revenue of $46.9 million, versus the firm's... More
Cytokinetics (CYTK) Tops Q4 EPS Views; Offers FY15 Outlook
February 12, 2015 4:13 PM ESTCytokinetics (NASDAQ: CYTK) reported Q4 EPS of $0.23, $0.40 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $21.8 million versus the consensus estimate of $10.8 million.
Financial Guidance
Cytokinetics also announced its financial guidance for 2015. The company anticipates cash... More
